[High-dose epirubicin in combination with high-dose ifosfamide plus granulocyte colony stimulating factor in patients with advanced platin-pretreated ovarian cancer. Phase I-II study].
Küffer
E
E
I. Univers.-Frauenklinik Wien.
Fazeny
B
B
Speiser
P
P
Kurz
C
C
Vavra
N
N
Sevelda
P
P
Dittrich
C
C
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology
D009944:Organoplatinum Compounds; D016179:Granulocyte Colony-Stimulating Factor; D015251:Epirubicin; D007069:Ifosfamide